ASP8374 + cemiplimab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Recurrent Glioblastoma
Trial Timeline
Mar 9, 2022 → Jan 1, 2024
NCT ID
NCT04826393About ASP8374 + cemiplimab
ASP8374 + cemiplimab is a phase 1 stage product being developed by Astellas Pharma for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04826393. Target conditions include Glioblastoma, Recurrent Glioblastoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04826393 | Phase 1 | Completed |
Competing Products
20 competing products in Glioblastoma